Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Extension CombiRx data show no benefit of combined MS drugs
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Role of regulatory b cells in neuroimmunologic disorders.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Interferon-β-1b: a review of its use in multiple sclerosis.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
NOVANTRONE. mitoXANTRONE for injection concentrate
Repurposing drugs for disease modification in multiple sclerosis
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes.
Merck: Regulatory Update on Cladribine Tablets

Pages